Abarelix Articles
SEP launches Plenaxis in Germany
3 March 2008
Praecis cuts workforce 60% in reshuffle
30 May 2005
New product launches in 2004
31 January 2005
Praecis and Schering AG sign Plenaxis accord
3 May 2004
FDA clears Praecis' prostate cancer drug
8 December 2003
Praecis updates on Plenaxis status
5 August 2002
Praecis' Plenaxis effective in endometriosis
1 July 2002
Praecis stops Latranal development
1 October 2001
Amgen pulls out of Plenaxis alliance
19 September 2001
US FDA rejects Amgen/Praecis cancer drug Plenaxis
14 June 2001
Stock Commentary - New York
7 June 2001
Positive Ph III data for Praecis' abarelix
6 June 2001
Amgen's 1st-qtr net income rises 15%
1 May 2001
Amgen notes delay in launch of Aranesp
1 May 2001
US NDA for Praecis' abarelix depot
14 December 2000
Sanofi-Synthelabo advanced-stage R&D
26 July 2000
Ph III data with Amgen/Praecis' cancer drug
25 May 2000
Amgen files first regulatory dossiers for NESP and Kineret
27 January 2000
Amgen sets aside $100m for abarelix in 1999
18 March 1999
Stock Commentary New York
18 March 1999
Sanofi-Synthelabo Merger Strong In Cardio, CNS
10 December 1998
First Half Sales At Roche Leap 41%, Boosted By BM
13 July 1998
Better News For Roche As Xenical Sees First Launch
18 June 1998
Showing 1-32 of 32 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
